FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

被引：0
|
作者：
Peterlin, Pierre [1 ]
Gaschet, Joelle [2 ]
Turlure, Pascal [3 ]
Gourin, Marie-Pierre [4 ]
Dumas, Pierre-Yves [5 ,6 ]
Thepot, Sylvain [7 ]
Berceanu, Ana [8 ]
Park, Sophie [9 ]
Cluzeau, Thomas [11 ]
Torregrosa-Diaz, Jose-Miguel [12 ]
Drevon, Louis [13 ]
Sapena, Rosa [14 ]
Chermat, Fatiha [14 ]
Dimicoli-Salazar, Sophie [15 ]
Jullien, Maxime [1 ]
Fenaux, Pierre [16 ]
Chevallier, Patrice [1 ]
机构：
[1] Nantes Univ Hosp, Nantes, France
[2] Univ Angers, Nantes Univ, CRCI2NA UMR INSERM CNRS 6075 1307, Nantes, France
[3] CHU Limoges, Serv Hematol Clin, Limoges, France
[4] CHU Limoges, Limoges, France
[5] CHU Bordeaux, Serv Hematol Clin & Therapie Cellulaire, F-33000 Bordeaux, France
[6] Univ Bordeaux, BRIC BoRdeaux Inst onCol, UMR1312, INSERM, F-33000 Bordeaux, France
[7] Angers Univ Hosp, Dept Clin Hematol, Angers, France
[8] CHU Besancon, Dept Clin Hematol, Besancon, France
[9] CHU Grenoble, Grenoble 9, France
[10] Inst Paoli Calmettes, Hematol Dept, Marseille, France
[11] CHU Nice, Nice, France
[12] Univ Poitiers Hosp, Poitiers, France
[13] St Louis Hosp Paris, Paris, France
[14] Grp Francophone Myelodysplasies, Paris, France
[15] Bordeaux Univ Hosp, Bordeaux, France
[16] Hop St Louis, Grp Francophone Myelodysplasies, Paris, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-173741
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 10 条
  • [1] OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA
    Medeiros, B. C.
    Hogge, D.
    Newell, L. F.
    Bixby, D. L.
    Solomon, S. R.
    Strickland, S. A.
    Lin, T. L.
    Erba, H.
    Powell, B. L.
    Podoltsev, N.
    Ryan, R.
    Chiarella, M.
    Louie, A. C.
    Lancet, J. E.
    HAEMATOLOGICA, 2017, 102 : 53 - 54
  • [2] CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS
    Lancet, J.
    Uy, G.
    Cortes, J.
    Newell, L.
    Lin, T.
    Ritchie, E.
    Strickland, S.
    Stuart, R.
    Hogge, D.
    Solomon, S.
    Stone, R.
    Bixby, D.
    Kolitz, J.
    Schiller, G.
    Wieduwilt, M.
    Rao, A.
    Rubenstein, S.
    Stock, W.
    Foster, M.
    Erba, H.
    Goldberg, S.
    Powell, B.
    Podoltsev, N.
    Atallah, E.
    Warlick, E.
    Yee, K.
    Pagel, J.
    Norkin, M.
    Barta, S.
    Sandhu, I.
    Frankfurt, O.
    Gautier, M.
    Larson, M.
    Seiter, K.
    Levy, M.
    Bergeron, J.
    Berdeja, J.
    Kropf, P.
    Shemanski, L.
    Ryan, D.
    Chiarella, M.
    Paulsen, K.
    Louie, A.
    Medeiros, B.
    HAEMATOLOGICA, 2016, 101 : 186 - 186
  • [3] Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality
    Walter, Roland B.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Othus, Megan
    Louie, Arthur C.
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [4] Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
    Medeiros, Bruno
    Hogge, Donna
    Newell, Laura
    Bixby, Dale
    Solomon, Scott
    Strickland, Stephen
    Lin, Tara
    Erba, Harry
    Powell, Bayard
    Podoltsev, Nikolai
    Ryan, Robert
    Chiarella, Michael
    Louie, Arthur
    Lancet, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S286 - S286
  • [5] Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).
    Medeiros, Bruno C.
    Hogge, Donna
    Newell, Laura F.
    Bixby, Dale L.
    Solomon, Scott R.
    Strickland, Stephen Anthony
    Lin, Tara L.
    Erba, Harry Paul
    Powell, Bayard L.
    Podoltsev, Nikolai Alexandrovich
    Ryan, Robert
    Chiarella, Michael
    Louie, Arthur
    Lancet, Jeffrey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
    Kolitz, Jonathan
    Strickland, Stephen
    Cortes, Jorge
    Hogge, Donna
    Lancet, Jeffrey
    Goldberg, Stuart
    Chung, Karen
    Ryan, Robert
    Chiarella, Michael
    Louie, Arthur
    Stuart, Robert
    Medeiros, Bruno
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S287 - S287
  • [7] Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
    Peterlin, Pierre
    Gaschet, Joelle
    Bertoli, Sarah
    Bernard, Marc
    Carre, Martin
    Dumas, Pierre-Yves
    Hunault, Mathilde
    Belhabri, Amine
    Banos, Anne
    Bonmati, Caroline
    Tavernier, Emmanuelle
    Guillerm, Gaelle
    Bonnet, Sarah
    Decroocq, Justine
    Saad, Alain
    Ojeda-Uribe, Mario
    Guieze, Romain
    Marchand, Tony
    Recher, Christian
    Garnier, Alice
    Vibet, Marie-Anne
    Chevallier, Patrice
    BLOOD, 2023, 142
  • [8] Event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance treatment based on a retrospective, blinded independent central review (BICR) of imaging during long-term follow-up
    Oesterheld, Javier E.
    Bergendahl, Genevieve
    Clinch, Thomas
    Gullo, Kristen
    Staines, Harry
    Bohl, Casey E.
    Kraveka, Jacqueline M.
    Ferguson, William
    Sholler, Giselle Linda Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
    Ritchie, Ellen K.
    Lin, Tara L.
    Newell, Laura F.
    Stuart, Robert K.
    Solomon, Scott R.
    Stone, Richard M.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Eileen A.
    Dronamraju, Nalina
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).
    Castellino, Sharon M.
    Pei, Qinglin
    Parsons, Susan K.
    Hodgson, David C.
    McCarten, Kathleen
    Punnett, Angela
    Horton, Terzah M.
    Dave, Hema Kishore
    Cho, Steve Y.
    Wu, Yue
    Henderson, Tara O.
    Hoppe, Bradford
    Keller, Frank G.
    Kelly, Kara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1